Scientific Co-Founder Dr. Ben Barres
We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye.
We target C1q to block all damaging components of the immune system’s classical complement pathway.Learn more
Our next generation of early complement inhibitors targets diseases of the body, brain and eye.Learn more
We are passionate about delivering transformative therapies for people suffering from devastating complement-driven diseases.Join us
Oct 04, 2021 | PDF VersionAnnexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer